{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:53Z","timestamp":1772119313603,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06059-2","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:06:39Z","timestamp":1730952399000},"page":"5807-5816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of different doses of rituximab on immunoglobulin levels in high-risk pediatrics with Burkitt\u2019s lymphoma"],"prefix":"10.1007","volume":"103","author":[{"given":"Shuang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaguang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2048-6397","authenticated-orcid":false,"given":"Yanlong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"6059_CR1","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","volume":"109","author":"MS Cairo","year":"2006","unstructured":"Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J (2006) Results of a randomized international study of high-risk central nervous system B non-hodgkin lymphoma and B acute lymphoblastic leukaemia in children and adolescents. Blood 109:2736\u20132743. https:\/\/doi.org\/10.1182\/blood-2006-07-036665","journal-title":"Blood"},{"key":"6059_CR2","doi-asserted-by":"publisher","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","volume":"34","author":"CV Minard","year":"2016","unstructured":"Minard CV, Auperin A, Pillon M, Burke A, Anderson JR, Donald A et al (2016) Results of the randomized intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of Rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. J Clin Oncol 34:10507. 10.1200\/JCO.2016.34.15_suppl.10507","journal-title":"J Clin Oncol"},{"key":"6059_CR3","doi-asserted-by":"crossref","unstructured":"Minard-Colin V, Aup\u00e9rin A, Pillon M (2020) Rituximab for High-Risk, mature B-Cell Non-hodgkin\u2019s lymphoma in children. N ENG J MED, 2207\u20132219","DOI":"10.1056\/NEJMoa1915315"},{"issue":"3","key":"6059_CR4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00277-023-05568-w","volume":"103","author":"H Shuang","year":"2024","unstructured":"Shuang H, Ling Jin, Jing Y et al (2024) Optimal dosage of Rituximab for children with Burkitt lymphoma. Ann Hematol 103(3):893\u2013903. https:\/\/doi.org\/10.1007\/s00277-023-05568-. Epub 2023 Dec 13","journal-title":"Ann Hematol"},{"key":"6059_CR5","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","volume":"33","author":"A Rosolen","year":"2015","unstructured":"Rosolen A, Perkins SL, Pinkerton CR (2015) Et a1.Revised International Pediatric non\u2014Hodgkin Lymphoma Staging System. J Clin Oncol 33:2112\u20132118","journal-title":"J Clin Oncol"},{"issue":"18","key":"6059_CR6","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.2014.59.0745","volume":"33","author":"JT Sandlund","year":"2015","unstructured":"Sandlund JT, Guillerman RP, Perkins SL et al (2015) International pediatric non-hodgkin lymphoma response criteria. J Clin Oncol 33(18):2106\u20132111","journal-title":"J Clin Oncol"},{"key":"6059_CR7","unstructured":"Zhong Xuhui D, Jie Z, Jianhua (2018) A multicenter study of reference intervals for 15 laboratory parameters in Chinese children. 56(11): 835\u2013845. DOI: 10.3760\/cma. j. issn. 0578-1310.2018. 11.009"},{"issue":"27","key":"6059_CR8","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2014","volume":"33","author":"V Minard-Colin","year":"2015","unstructured":"Minard-Colin V, Brugieres L, Reiter A et al (2015) Non-hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol 33(27):2963\u20132974. https:\/\/doi.org\/10.1200\/JCO.2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"6059_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ajh.22189","volume":"87","author":"G Todeschini","year":"2012","unstructured":"Todeschini G, Bonifacio M, Tecchio C et al (2012) Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma\/leukemia. Am J Hematol 87(1):22\u201325. https:\/\/doi.org\/10.1002\/ajh.22189","journal-title":"Am J Hematol"},{"issue":"9","key":"6059_CR10","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00277-017-3044-4","volume":"96","author":"M Cremer","year":"2017","unstructured":"Cremer M, Schwarzbich MA, Schoning T, Lisenko K, Ho AD, Witzens-Harig M (2017) Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study. Ann Hematol 96(9):1573\u20131575. https:\/\/doi.org\/10.1007\/s00277-017-3044-4","journal-title":"Ann Hematol"},{"key":"6059_CR11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/leu.2012.255","volume":"27","author":"S Goldman","year":"2013","unstructured":"Goldman S, Smith L, Anderson JR et al (2013) Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-hodgkin lymphoma: a children\u2019s Oncology Group report. Leukemia 27:1174\u20131177","journal-title":"Leukemia"},{"issue":"1","key":"6059_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers7010305","volume":"7","author":"J Worch","year":"2015","unstructured":"Worch J, Makarova O, Burkhardt B (2015) Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? [J]. Cancers (Basel) 7(1):305\u2013328. https:\/\/doi.org\/10.3390\/cancers7010305","journal-title":"Cancers (Basel)"},{"issue":"6","key":"6059_CR13","doi-asserted-by":"publisher","first-page":"e2077","DOI":"10.1002\/rmv.2077","volume":"29","author":"D Focosi","year":"2019","unstructured":"Focosi D, Tuccori M, Maggi F (2019) Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of Rituximab. Rev Med Virol 29(6):e2077","journal-title":"Rev Med Virol"},{"key":"6059_CR14","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","volume":"28","author":"A Meinhardt","year":"2010","unstructured":"Meinhardt A, Burkhardt B, Zimmer-mann M et al (2010) Phase II window study on Rituximab in newly diagnosed pediatric mature B-cell non-hodgkin\u2019s lymphoma and Burkitt leukemia. J Clin Oncol 28:3115\u20133121","journal-title":"J Clin Oncol"},{"key":"6059_CR15","doi-asserted-by":"publisher","unstructured":"Zijun Zhen J, Zhu X Sun, Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk groups R2 to R4.Pediatric Hematology and Oncology. https:\/\/doi.org\/10.1080\/08880018.2020.1759741","DOI":"10.1080\/08880018.2020.1759741"},{"key":"6059_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","volume":"58","author":"SV Onrust","year":"1999","unstructured":"Onrust SV, Lamb HM, Balfour JA (1999) Rituximab Drugs 58:79\u201388","journal-title":"Rituximab Drugs"},{"issue":"10036","key":"6059_CR17","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140","volume":"387","author":"V Ribrag","year":"2016","unstructured":"Ribrag V, Koscielny S, Bosq J et al (2016) Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 387(10036):2402\u20132411. https:\/\/doi.org\/10.1016\/S0140-","journal-title":"Lancet"},{"key":"6059_CR18","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med ;346: 235\u2009\u2013\u200942","DOI":"10.1056\/NEJMoa011795"},{"key":"6059_CR19","doi-asserted-by":"publisher","unstructured":"Roxane Labrosse S, Barmettler Beata Derfalvi,et.al Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients American Academy of Allergy. Asthma Immunol 2021 (03): 523\u2013532. https:\/\/doi.org\/10.1016\/j.jaci.2021.03.041","DOI":"10.1016\/j.jaci.2021.03.041"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06059-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:13:29Z","timestamp":1735848809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06059-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6059"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06059-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4304714\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Beijing Children\u2019s Hospital (IEC-C008-A08-V.05.1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed informed consent sheets and consented to the publication of their anonymize data in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}